Item 7.01 |
Regulation FD Disclosure.
|
On October 14, 2022, Renovacor, Inc. (the “Company,” or
“Renovacor”) updated information reflected in a slide presentation,
which is attached as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated
herein by reference. Representatives of the Company will use the
updated presentation in various meetings from time to time.
The information furnished pursuant to Item 7.01, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, and shall not be deemed
to be incorporated by reference in any filing under the Securities
Act of 1933, as amended, or Exchange Act, except as expressly set
forth by specific reference in such filing.
Important Additional Information Regarding the Transaction Will Be
Filed With the SEC
In connection with the proposed transaction between Renovacor and
Rocket Pharmaceuticals, Inc. (“Rocket”), Renovacor and Rocket have
filed relevant materials with the SEC, including a Rocket
registration statement on Form S-4 that includes a joint proxy
statement of Renovacor and Rocket and also constitutes a prospectus
of Rocket, and a definitive proxy statement will be mailed to
stockholders of Renovacor and Rocket, respectively. INVESTORS AND
SECURITY HOLDERS OF RENOVACOR AND ROCKET ARE URGED TO READ THE
JOINT PROXY STATEMENT/PROSPECTUS THAT HAS BEEN INCLUDED IN THE
REGISTRATION STATEMENT ON FORM S-4 AND OTHER RELEVANT DOCUMENTS FILED
OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED
TRANSACTION OR INCORPORATED BY REFERENCE IN THE JOINT PROXY
STATEMENT/PROSPECTUS (IF ANY) CAREFULLY AND IN THEIR ENTIRETY WHEN
THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION, THE PARTIES
TO THE PROPOSED TRANSACTION AND THE RISKS ASSOCIATED WITH THE
PROPOSED TRANSACTION. Investors and security holders will be able
to obtain, without charge, a copy of the registration statement,
the joint proxy statement/prospectus and other relevant documents
filed with the SEC (when available) from the SEC’s website at
http://www.sec.gov.
Copies of the documents filed with the SEC by Renovacor will be
available free of charge on Renovacor’s internet website at
www.renovacor.com
under the tab “Investor & Media - Financials” or by
contacting Renovacor’s Investor Relations Department at
investors@renovacor.com.
Copies of the documents filed with the SEC by Rocket will be
available free of charge on Rocket’s internet website at
www.rocketpharma.com
under the tab “Investors - SEC Filings”.
Participants in the Solicitation
Renovacor, Rocket and certain of their directors, executive
officers and other members of management may be deemed to be
participants in the solicitation of proxies with respect to the
proposed transaction. Information regarding the persons who may,
under the rules of the SEC, be deemed participants in the
solicitation of the shareholders of Renovacor or Rocket in
connection with the proposed transaction, including a description
of their direct or indirect interests, by security holdings or
otherwise, have been set forth in the joint proxy
statement/prospectus that has been filed with the SEC. Information
regarding Renovacor’s directors and executive officers is contained
in Renovacor’s definitive proxy statement, which was filed with the
SEC on April 14, 2022, and Renovacor’s Current Reports on Form
8-K, filed with the SEC on
March 28, 2022 and June 3, 2022 (as amended on
June 24, 2022). Information regarding Rocket’s directors and
executive officers is contained in Rocket’s definitive proxy
statement, which was filed with the SEC on April 29, 2022.
Security holders and investors may obtain additional information
regarding the interests of such persons, which may be different
than those of Renovacor’s or Rocket’s security holders generally,
by reading the joint proxy statement/prospectus and other relevant
documents regarding the transaction, which will be filed with the
SEC. You may obtain these documents (when they become available)
free of charge through the website maintained by the SEC at
http://www.sec.gov
and from the Investor Relations websites of Rocket or Renovacor as
described above.
No Offer or Solicitation
This communication is not intended to and does not constitute an
offer to sell or the solicitation of an offer to subscribe for or
buy or an invitation to purchase or subscribe for any securities or
the solicitation of any vote or approval in any jurisdiction
pursuant to the proposed transaction or otherwise, nor shall there
be any sale, issuance